Gilead to buy US biotech Arcellx for up to $7.8 billion
Gilead to buy US biotech Arcellx for up to $7.8 billion is drawing significant interest across the industry.
Silicon Valley-based Gilead is hunting for deals to expand beyond its focus on antiviral medicine into cancer and other disease areas, after forecasting full-year sales that fell short of analyst estimates this month.
Experts suggest this could influence future trends and innovation in the sector.
More updates are expected as the story develops.
Related Articles
- US Navy's new facility to advance submarine
- HSC paper leak: FIR lodged, city tuition teacher suspect
- Can private lenders fill the student loan gap? College presidents say no.
- Organizers announce lineup for 12th annual Blue Ox Music Festival
Source: Original →